GlassScriptPhysician profile
Nancy L Cheeks
NPI 1588146633
$1,774.67
in general payments reported to CMS, 2019-2025
13 companies · $513 in 2025
The $513 reported for 2025 was more than what 75% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $114 · 2023: $646 · 2024: $501 · 2025: $513.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,523 · Education: $137.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,523.35 |
| Education | $136.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $575.80 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $313.38 | 2023-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $201.14 | 2022-2025 | Mounjaro, Zepbound, Emgality |
| Amgen INC. | $156.73 | 2023-2025 | Repatha, Repatha, Otezla |
| Novo Nordisk INC | $141.09 | 2022-2025 | Rybelsus, Ozempic, Wegovy |
| Astellas Pharma US INC | $105.19 | 2024 | Veozah |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $82.14 | 2023-2025 | Caplyta |
| Pfizer INC. | $57.90 | 2022-2025 | |
| Glaxosmithkline, LLC. | $45.94 | 2023-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Corcept Therapeutics | $27.82 | 2024-2025 | Korlym |
| Axsome Therapeutics, INC. | $27.79 | 2025 | Auvelity |
| Teva Pharmaceuticals USA, INC. | $23.96 | 2025 | Austedo Xr |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.79 | 2023 | Stiolto Respimat |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nancy Cheeks listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.